Welcome to Our Blog
Here you will find quality thought on Pricing and other topics from EBITDA Catalyst.
Footwear Pricing Strategy: Who Will “Just Do It”?
Part 1: Will Footwear Brands Raise Prices In 2022? Many footwear brands have signaled intent to raise prices in 2022, and a select few have
Grocery Prices Inflation: Cub Foods – A Poor Value?
Share on linkedin Share on email Share on print Cub Foods is priced 60%+ higher than key competitors Many people may be noticing higher grocery
Hope Is Not A Strategy: Drug Prices Impact On Medicare & Taxpayers
Introduction Lately, my LinkedIn feed has been persistently featuring this Alzheimer’s Association post. It calls for everyone to protest the draft decision by CMS (Centers
“Keep Climbing” Indeed: Delta’s Basic Economy Fares & Shrinkflation With Clever Twists
Summary / TLDR Delta’s motto, currently “Keep Climbing”, seems a bit more apropos these days. On December 10, Delta landed some bad news on price-conscious
Uber-Charged: The DOJ, Uber’s “Wait Time Fee”, and Some Pricing Common Sense
Legitimate Pricing Strategy, Poor Execution? The Department of Justice has sued Uber for charging “wait time” fees to passengers who, because of disability, need more
Peloton’s Pricing Strategy: Racing Into Trouble?
Sometimes, an inflexible, one-size-fits-all pricing strategy can turn into a major liability in a rapidly changing market. On Friday, November 5, shares of Peloton fell
Pruning Customers to Increase Profitability In A Supply-Constrained Environment
Many companies operate on the assumption that any customer providing “some” additional contribution margin is a good customer. Surely having it is better than the
The Fed Needs to Get Real about Inflation
Federal Reserve chairman Jerome Powell loves to use the word “transitory” to describe the threat of inflation. But with each passing day, it looks more
Pharmaceutical Company AbbVie Inflated Prices for Two Major Drugs, House Oversight Report Says
Pharmaceutical company AbbVie significantly inflated prices over the past two decades for patients in the U.S. who take the drugs Humira and Imbruvica, a report
